Revenue from Contract with Customer, Excluding Assessed Tax of KalVista Pharmaceuticals, Inc. from 30 Apr 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
KalVista Pharmaceuticals, Inc. quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 30 Apr 2017 to 30 Sep 2025.
  • KalVista Pharmaceuticals, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 30 Sep 2025 was $13,692,000.
  • KalVista Pharmaceuticals, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2019 was $12,690,000, a 21% decline from 2018.
  • KalVista Pharmaceuticals, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2018 was $16,127,000, a 92% increase from 2017.
  • KalVista Pharmaceuticals, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2017 was $8,394,000, a 458% increase from 2016.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $13,692,000 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $1,426,000 01 May 2025 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q1 2020 $12,690,000 $3,824,000 +$898,000 +31% 01 Feb 2020 30 Apr 2020 10-K 01 Jul 2020 2020 FY
Q4 2019 $11,792,000 $1,577,000 -$2,313,000 -59% 01 Nov 2019 31 Jan 2020 10-Q 11 Mar 2021 2021 Q3
Q3 2019 $14,105,000 $3,920,000 -$1,672,000 -30% 01 Aug 2019 31 Oct 2019 10-Q 10 Dec 2020 2021 Q2
Q2 2019 $15,777,000 $3,369,000 -$349,000 -9.4% 01 May 2019 31 Jul 2019 10-Q 14 Sep 2020 2021 Q1
Q1 2019 $16,126,000 $2,926,000 -$1,914,000 -40% 01 Feb 2019 30 Apr 2019 10-K 01 Jul 2020 2020 FY
Q4 2018 $18,040,000 $3,890,000 +$1,559,000 +67% 01 Nov 2018 31 Jan 2019 10-K 01 Jul 2020 2020 FY
Q3 2018 $16,481,000 $5,592,000 +$4,465,000 +396% 01 Aug 2018 31 Oct 2018 10-K 01 Jul 2020 2020 FY
Q2 2018 $12,016,000 $3,718,000 +$3,622,000 +3773% 01 May 2018 31 Jul 2018 10-K 01 Jul 2020 2020 FY
Q1 2018 $8,394,000 $4,840,000 01 Feb 2018 30 Apr 2018 10-K 16 Jul 2019 2019 FY
Q4 2017 $2,331,000 01 Nov 2017 31 Jan 2018 10-K 16 Jul 2019 2019 FY
Q3 2017 $1,127,000 01 Aug 2017 31 Oct 2017 10-K 16 Jul 2019 2019 FY
Q2 2017 $96,000 01 May 2017 31 Jul 2017 10-K 16 Jul 2019 2019 FY

KalVista Pharmaceuticals, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2019 $12,690,000 -$3,437,000 -21% 01 May 2019 30 Apr 2020 10-K 07 Jul 2022 2022 FY
2018 $16,127,000 +$7,733,000 +92% 01 May 2018 30 Apr 2019 10-K 13 Jul 2021 2021 FY
2017 $8,394,000 +$6,890,000 +458% 01 May 2017 30 Apr 2018 10-K 01 Jul 2020 2020 FY
2016 $1,504,000 01 May 2016 30 Apr 2017 10-K 16 Jul 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.